LONG MINI-FUTURE - GENMAB | Market Closed - Börse Stuttgart 02:29:29 2024-06-20 am EDT | ||
| 9.93 EUR | -5.43% |
|
| Current month | -18.07% | ||
| 1 month | -27.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 9.93 | -5.43% |
| 24-06-19 | 10.5 | +1.35% |
| 24-06-18 | 10.36 | -2.17% |
| 24-06-17 | 10.59 | -1.03% |
| 24-06-14 | 10.7 | -1.47% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 02:29 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VA80VR |
| ISIN | DE000VA80VR3 |
| Date issued | 2018-10-30 |
| Strike | 1,012 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 32.31 € |
|---|---|
| Lowest since issue | 1.21 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,806
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.43%
- Stock Market
- Certificates
- Certificat
